Fusen Pharmaceutical(01652) Key Financial Indicators

Quotes

Detailed Quotes

Company Overview

Company Profile Company Executives

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

YOY

Do not show

Hide blank lines

(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30

Per Share IndicaTor

Operating Cash Flow Per Share

-67.74% 0.0759 -62.07% 0.0559 726.56% 0.2352 471% 0.1473

Cash Flow Per Share

-609.35% -0.341 -485.11% -0.3785 85.36% -0.0481 128.72% 0.0983

Operating Income Per Share

-18.02% 0.6127 -3.01% 0.3344 31.46% 0.7474 23.5% 0.3447

Net Asset Per Share

3.29% 1.0455 16.78% 1.0884 7.72% 1.0123 3.74% 0.932

Basic Earning Per Share

-77.12% 0.0245 64.67% 0.0721 36.84% 0.1069 28.4% 0.0438

Diluted Earning Per Share

-77.12% 0.0245 64.67% 0.0721 36.84% 0.1069 28.4% 0.0438

Profitability

Gross Profit Ratio

0.17% 54.745% 2.84% 55.194% 4.78% 54.650% -1.31% 53.669%

Operating Profit Ratio

6.36% 13.519% 60.71% 21.870% -21.72% 12.711% -17.76% 13.608%

Net Profit Ratio

-66.53% 4.308% 51.41% 20.451% 0.34% 12.872% 11.8% 13.507%

Earning Before Tax Ratio

-61.69% 6.169% 40.15% 23.713% 2.81% 16.104% 20.54% 16.920%

ROE

-76.39% 2.563% 26.34% 6.510% 32.3% 10.855% 36.15% 5.153%

ROA

-77.22% 1.361% 21.22% 3.497% 32.47% 5.978% 38.36% 2.885%

Yield Quality

Operating Profit To Total Profits

177.66% 219.146% 14.67% 92.226% -23.86% 78.927% -31.77% 80.426%

Tax To Total Profits

-50.32% -30.171% 31.8% -13.757% -10.85% -20.071% -44.77% -20.171%

Operating Cash To Total Revenue

-60.64% 12.385% -60.89% 16.713% 528.74% 31.469% 400.41% 42.735%

Capital Structure

Debt Assets Ratio

0.04% 46.992% 2.11% 45.834% 11.69% 46.973% 7.34% 44.886%

Equity Multipler

0.03% 1.883 0.84% 1.8427 7.78% 1.8824 5.14% 1.8273

Debt Equity Ratio

0.08% 88.652% 3.9% 84.616% 22.04% 88.583% 13.33% 81.442%

Current Assets To tatal Assets

-22.76% 41.088% -36.64% 35.859% -7.22% 53.198% -6.43% 56.599%

Non Current Assets To Total Assets

25.87% 58.912% 47.79% 64.141% 9.7% 46.802% 9.85% 43.401%

Current Liabilities To tatal Liabilities

-10.55% 84.010% 0.29% 93.542% 0.82% 93.913% -3.73% 93.274%

Non Current Liabilities To Total Liabilities

162.7% 15.990% -3.99% 6.458% -11.13% 6.087% 116.17% 6.726%

Solvency

Current Ratio

-13.69% 1.0408 -38.13% 0.8364 -17.6% 1.2059 -9.46% 1.3519

Quick Ratio

-21.87% 0.7918 -47.32% 0.6161 -20.31% 1.0134 -7.77% 1.1695

Operating Profit To Current Liabilities

-5.7% 0.1066 29.26% 0.085 -21.28% 0.113 -9.9% 0.0658

Operrating Cash Flow To Current Liabilities

-65.1% 0.0976 -68.55% 0.065 532.28% 0.2798 429.13% 0.2066

Share Equity Without Minority Interest To Total Liabilities

-0.07% 1.1301 -2.88% 1.184 -16.93% 1.1309 -11.4% 1.2192

Operating Cash Flow To Total Liabilities

-68.78% 0.082 -68.46% 0.0608 537.46% 0.2627 416.85% 0.1927

Operating Profit To Total Liabilities

-15.65% 0.0895 29.63% 0.0796 -20.63% 0.1061 -13.26% 0.0614

Operating Capacity

Current Assets Turnover（T）

-10.92% 0.6703 7.23% 0.3847 45.92% 0.7525 41.91% 0.3588

Fixed Assets Turnover（T）

-45.17% 1.5033 -53.68% 0.7711 -4.79% 2.7417 28.99% 1.6647

Total Assets Turnover（T）

-23.98% 0.3154 -16.55% 0.1705 20.62% 0.415 18.05% 0.2044

Growth Ability

Operating Revenue GR 3Y

-254.25% -10.552% -- -20.175% 185.95% 6.841% -- --

Gross Income GR 3Y

-241.81% -10.770% -- -20.422% 183.28% 7.595% -- --

Operating Profit GR 3Y

-18.59% -58.937% -- -36.571% -12.18% -49.696% -- --

EBT GR 3Y

-140.17% -79.408% -- -22.478% 25.66% -33.064% -- --

Net Profit GR 3Y

-130.1% -82.530% -- -17.012% 21.61% -35.867% -- --

Net Profit Attributable To The Parent Company GR 3Y

-194% -82.492% -- -16.818% 36.05% -28.059% -- --

Total Assets GR 3Y

-52.13% 13.909% -- 49.097% 1224.69% 29.054% -- --

Share Equity Without Minority Interest GR 3Y

-94.4% 14.620% -- 203.757% -42.77% 261.162% -- --

Equity GR 3Y

-94.53% 14.005% -- 200.440% -41.57% 256.145% -- --

Total Liabilities GR 3Y

155.29% 13.800% -- -6.541% 51.73% -24.961% -- --

Basic Earning Per Share GR 3Y

-94.21% -85.711% -- -32.450% 21.63% -44.133% -- --

Net Assets Per Share GR 3Y

-- 19.096% -- 136.714% -- -- -- --

Other Indicators

Currency Unit

HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

Company Overview More

Fusen Pharmaceutical Co., Ltd. is a Chinese company that mainly provides Shuanghuanglian cold medicine. The company is mainly engaged in the R & D, production and sales of a variety of proprietary Chinese medicine and western medicine products for the treatment of cold and fever, cardiovascular disease and anemia. The company's main products include small volume injections, oral liquids, tablets, capsules and granules. The company mainly sells its products in the domestic market.

CEO： Changcheng Cao

Market： Hong Kong motherboard

Hot List

TradeSearchNews

SymbolLatest price%Chg